- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnology. 2016 Academic Article GET IT
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Times cited: 73
- Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer discovery. 2014 Academic Article GET IT
- Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT